Bifogade filer
Kurs & Likviditet
Beskrivning
Land | Danmark |
---|---|
Lista | First North Stockholm |
Sektor | Hälsovård |
Industri | Bioteknik |
Hørsholm, Denmark, June 13, 2022 - ExpreS2ion Biotech Holding AB's affiliate ExpreS2ion Biotechnologies ApS ("ExpreS2ion") announces that Analysguiden has updated their research reports on ExpreS2ion in June, following the publication of Q1 2022 results, the positive Phase II COVID-19 results for the ABNCoV2 vaccine with respect to omicron protection, and progression of the preclinical-stage breast cancer vaccine candidate ES2B-C001. Analysguiden sets a price target of SEK 30, based on a revised forecast of market size and likelihood of approval, while estimating an optimistic scenario resulting in a fair value of SEK 60.
The research report is available on the Analyst Reports (https://investor.expres2ionbio.com/analyst-reports/) page of ExpreS[2]ion's investor website, as well as on Analysguiden's web-page (https://www.aktiespararna.se/analysguiden/Hitta-Bolag/health-care/expres2ion-biotech-holding/expres2ion-biotech-holding-ab) (at both sites in Swedish and English).
Certified Adviser
Svensk Kapitalmarknadsgranskning AB
Telefon: +46 11 32 30 732
E-post: ca@skmg.se